Is short duration trastuzumab adequate adjuvant therapy for HER-2 overexpressing breast cancers?

Simple item page
dc.contributor.authorGoyal, Lovenishen_US
dc.contributor.authorGupta, Sudeepen_US
dc.date.accessioned2006-09-06en_US
dc.date.accessioned2009-06-03T05:06:09Z
dc.date.available2006-09-06en_US
dc.date.available2009-06-03T05:06:09Z
dc.date.issued2006-09-06en_US
dc.description.affiliationDepartment of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra.en_US
dc.identifier.citationGoyal L, Gupta S. Is short duration trastuzumab adequate adjuvant therapy for HER-2 overexpressing breast cancers? National Medical Journal of India. 2006 Sep-Oct; 19(5): 264-5en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/118144
dc.language.isoengen_US
dc.source.urihttps://www.nmji.inen_US
dc.titleIs short duration trastuzumab adequate adjuvant therapy for HER-2 overexpressing breast cancers?en_US
dc.typeJournal Articleen_US
Files
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.79 KB
Format:
Plain Text
Description:
Download
Collections
National Medical Journal of India